TH-CAR-027 for Grade 4 Gliomas

NCT07384390 | Not Yet Recruiting Early Phase 1 DMC

• 1 other identifier: 2025IIT-C0019
• Study Type: interventional
• Target: 21
• Locations: 0 countries
• Sites: N/A

Brief Summary

This is an open-Label, dose-escalation, multiple administration, exploratory clinical study to evaluate the safety, tolerability, and anti-tumor activity of TH-CART-027 cell injection in subjects with recurrent or progressive grade 4 glioma

Conditions

R/R Grade 4 Glioma

Outcome Measures

Primary Outcomes (2)

• Safety：Incidence of Dose Limiting Toxicity (DLT)

  Limiting toxicity type, incidence, and severity of dose limiting toxicities (DLTs) within 28 days after the first TH-CART-027 infusion

  28 days after the first TH-CART-027 infusion

• Safety：Incidence and severity of adverse events (AEs)

  To evaluate possible adverse events after TH-CAPT-027 infusion, including the incidence and severity of AEs.

  Six months post CAR-T cells infusion.

Secondary Outcomes (4)

• Overall survival (OS)

  12 and 24 months post CAR-T cells infusion

• Objective response rate (ORR)

  3 months post CAR-T cells infusion

• Progression Free Survival (PFS)

  1 year post CAR-T cells infusion

• Disease Control Rate (DCR)

  1 year post CAR-T cells infusion

Study Arms (1)

TH-CART-027

EXPERIMENTAL

mutliple-dosing, intratumoral and/or intraventricular infusion

Drug: TH-CART-027

Interventions

TH-CART-027 DRUG

Multiple-dosing, intratumoral and/or intraventricular infusion

TH-CART-027

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• \. Voluntarily participate in the clinical trial; fully understand and are informed about this study and sign the informed consent form; willing and able to comply with and complete all trial procedures.
• \. Male or female patients aged ≥18 years and ≤75 years. 3. Disease Status: Diagnosis of Grade 4 glioma as defined by the 2021 WHO Classification of Tumors of the Central Nervous System, including but not limited to glioblastoma, Grade 4 astrocytoma, and diffuse hemispheric glioma. Subjects must have experienced relapse or progression following standard therapy and are unsuitable for or refuse further surgical resection. Subjects with specific genetic mutations (e.g., NTRK gene fusion or BRAF V600E mutation) must have progressed after receiving corresponding targeted therapy to be eligible. Documentation of relapse/progression must include imaging (MRI or PET) or histopathological confirmation.
• \. B7-H3 Expression: ≥30% positivity for B7-H3 molecule in primary/relapsed tumor tissue by pathological testing. B7-H3 positivity is defined as: the percentage of B7-H3-positive tumor cells among total viable tumor cells in non-necrotic tumor tissue areas ≥30%.
• \. Karnofsky Performance Status (KPS) score ≥60, or Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
• \. Adequate venous access for peripheral blood mononuclear cell (PBMC) collection.
• \. Left ventricular ejection fraction (LVEF) ≥40% by cardiac ultrasound within one month prior to screening.
• \. Resting oxygen saturation ≥95% while breathing room air. 9. Laboratory tests must meet the following criteria within the specified timeframe prior to screening:
• Hematological Function: Absolute neutrophil count (ANC)≥1.5×10\^9/L, hemoglobin ≥90 g/L, platelet count≥100×10\^9/L, absolute lymphocyte count≥0.15×10\^9/L. No transfusion,granulocyte (macrophage)colony-stimulating factor, recombinant human erythropoietin, recombinant human thrombopoietin, thrombopoietin receptor agonist, recombinant human interleukin-11, or other supportive therapy within 14 days prior to the test.
• Liver Function: Total bilirubin≤1.5×upper limit of normal (ULN) (except for patients with Gilbert's syndrome characterized by persistent or recurrent unconjugated hyperbilirubinemia in the absence of hemolysis or hepatic pathology); Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST)≤2.5×ULN.
• Renal Function: Serum creatinine ≤1.5×ULN.
• Coagulation: Prothrombin time (PT) or activated partial thromboplastin time (aPTT) or international normalized ratio (INR) ≤1.5 ×ULN, in the absence of therapeutic anticoagulation.
• \. Female subjects of childbearing potential must have a negative urine or serum pregnancy test. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test is required. Female subjects of childbearing potential must use highly effective contraception from the start of the trial until 6 months after the last dose of study treatment. Sexually active males, who have not undergone vasectomy, must agree to use barrier contraception from the start of the trial until 6 months after the last dose of study treatment.

You may not qualify if:

• Subjects with a known history of severe allergy to any component of the investigational product.
• Pregnant or lactating women. Body weight \<40 kg.
• Viral Infections:
• <!-- -->
• Seropositivity for HIV antibody or positive serological test for Treponema pallidum (syphilis).
• Hepatitis B surface antigen (HBsAg) positivity with peripheral blood HBV DNA levels above the upper limit of normal.
• Hepatitis C virus (HCV) antibody positivity with detectable peripheral blood HCV RNA.
• Medical History and Concurrent Conditions:
• <!-- -->
• Having undergone carmustine wafer implantation surgery within the past 6 months.
• Known or suspected active autoimmune diseases, including but not limited to Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus, etc.
• Current requirement for systemic immunosuppressive therapy or, in the investigator's judgment, a need for long-term immunosuppressant use during the study period. Intermittent use of topical, inhaled, or intranasal corticosteroids is allowed.
• Uncontrolled psychiatric disorders. Or subjects with a medical or psychiatric history that, in the investigator's opinion, could increase the risk associated with study participation or administration of the study drug, or could interfere with the interpretation of results.
• Toxicities from prior anticancer therapy have not recovered to ≤ Grade 1 per CTCAE version 5.0 (except for alopecia and other events deemed tolerable by the investigator).
• Participation in another interventional clinical trial within the past 1 month.

Sponsors & Collaborators

• Shanghai Tongji Hospital, Tongji University School of Medicine: lead

Central Study Contacts

Feng Chen Dr., PhD

CONTACT

+86 21-66111652; ndrchen@163.com

Study Design

• Study Type: interventional
• Phase: early phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Director， Prof.

Study Record Dates

• First Submitted: January 26, 2026
• First Posted: February 3, 2026
• Study Start: January 30, 2026
• Primary Completion (Estimated): August 31, 2028
• Study Completion (Estimated): August 31, 2029
• Last Updated: February 4, 2026

Record last verified: 2026-02

Data Sharing

• IPD Sharing: Will not share